FATE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.9 USD | +5.41% |
|
-4.88% | +4.28% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 4.73M | Sales 2025 * | 4.85M | Capitalization | 444M |
|---|---|---|---|---|---|
| Net income 2024 * | -195M | Net income 2025 * | -211M | EV / Sales 2024 * | 51.2 x |
| Net cash position 2024 * | 202M | Net cash position 2025 * | 124M | EV / Sales 2025 * | 65.9 x |
| P/E ratio 2024 * |
-2.09
x | P/E ratio 2025 * |
-2.3
x | Employees | 181 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fate Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +5.41% | ||
| 1 week | -4.88% | ||
| Current month | -1.27% | ||
| 1 month | -42.31% | ||
| 3 months | -38.00% | ||
| 6 months | +83.10% | ||
| Current year | +4.28% |
1 week
3.58
4.26
1 month
3.586.37
Current year
3.468.83
1 year
1.638.83
3 years
1.6397.43
5 years
1.63121.16
10 years
1.46121.16
| Managers | Title | Age | Since |
|---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
| Chairman | 76 | 11-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 69 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.95% | 0 M€ | 0.00% | - | |
| 2.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 3.9 | +5.41% | 3,902,975 |
| 24-05-08 | 3.7 | -4.64% | 2,918,187 |
| 24-05-07 | 3.88 | -8.06% | 1,983,083 |
| 24-05-06 | 4.22 | +3.94% | 2,228,606 |
| 24-05-03 | 4.06 | -0.98% | 2,025,167 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
3.9
USD
Average target price
7.8
USD
Spread / Average Target
+100.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.28% | 444M | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +3.20% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -37.64% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- FATE Stock